Avidity of antineurocytoskeletal antibodies in Alzheimer's disease patients

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017 Jun;161(2):179-186. doi: 10.5507/bp.2017.017. Epub 2017 Apr 26.

Abstract

Aims: To optimise the ELISA method for the avidity of IgG antibodies against neurofilament heavy chain (NfH) and to determine the levels and avidity of anti-NfH antibodies in patients with Alzheimer's disease (AD) and a healthy control group.

Methods: Various dilutions of sera and concentrations of urea and sodium chloride as chaotropic reagents were tested in the process of the ELISA optimisation. The levels and avidity of anti-NfH antibodies were determined in 30 patients with Alzheimer's disease and 30 age-matched cognitively normal elderly adults.

Results: Sera dilution 1:200 and urea as a chaotrope in a concentration 6 mol/L were chosen to be the most suitable for the avidity assay of anti-NfH antibodies by ELISA. The results showed no differences in either level or avidity of IgG anti-NfH antibodies between AD patients and cognitively normal persons. The levels of anti-NfH IgG antibodies inversely correlated with their avidities.

Conclusions: We optimised the ELISA method for the determination of anti-NfH antibody avidity determination which is suitable for research of anti-NfH antibody avidity in patients with neurological diseases associated with neurocytoskeletal defects. The determination of serum anti-NfH antibody avidity in AD patients seems to have limited diagnostic significance.

Keywords: Alzheimer's disease; antibodies; avidity; heavy chain of neurofilament; neurofilament.

MeSH terms

  • Aged
  • Alzheimer Disease / blood*
  • Alzheimer Disease / immunology*
  • Antibodies / blood*
  • Antibody Affinity / drug effects*
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Immunoglobulin G / blood*
  • Intermediate Filaments / drug effects*
  • Male

Substances

  • Antibodies
  • Immunoglobulin G